AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nuvalent Announces FDA Acceptance of Zidesamtinib NDA for ROS1-Positive NSCLC.
ByAinvest
Wednesday, Jan 14, 2026 6:33 am ET1min read
NUVL--
Nuvalent has announced progress in its OnTarget 2026 operating plan, including an FDA acceptance of its NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC patients. The PDUFA target action date is September 18, 2026. The company plans to submit an NDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC patients in the first half of 2026 and a potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC patients in the second half of 2026. Nuvalent is well capitalized with an operating runway anticipated into 2029.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet